Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.
|Articles|March 30, 2011
Welcome to Photoclinic Pediatrics
Dermclinic features clinical cases with images submitted by pediatricians. These cases are chosen for their teaching value. We invite you to submit your own cases and share them with colleagues.
Advertisement
Dermclinic features clinical cases with images submitted by pediatricians. These cases are chosen for their teaching value. We invite you to submit your own cases and share them with colleagues.
Please send your cases to
Dermclinic Submission Guidelines
Advertisement
Related to this article
Real-world claims show dupilumab was tied to a 33%-52% lower risk of atopic march progression vs systemic corticosteroids in children with AD.
Once-daily roflumilast cream 0.05% was well tolerated in infants 3 to <24 months with AD, with 34.4% reaching vIGA-AD success at week 4.
Oral icotrokinra kept PASI 90 rates at ≥72% and IGA 0/1 at ≥70% from week 64 to 112 in ICONIC-LEAD, with no new safety signals.
At AAP 2026, Justin Wheeler, MD, discussed bowel cleanouts, maintenance therapy, and behavioral strategies for managing constipation in children.
Justin Wheeler, MD, explains how pediatricians can identify constipation across age groups and distinguish overflow incontinence from diarrhea.
Nichole Tyson, MD, outlines how pediatricians can evaluate menstrual concerns, identify red flags, and determine when specialty care is needed.
At AAP 2026, Stephen Bondi, JD, MD, FAAP, outlined steps pediatricians should take after receiving notice of a malpractice claim.
Advertisement
Advertisement
Trending on Contemporary Pediatrics
1
Consistency key to managing pediatric constipation
2
Dupilumab tied to lower atopic march risk vs steroids in children
3
Maternal egg-peanut diet doesn't prevent infant allergy
4
Roflumilast cream 0.05% shows early AD clearance in infants
5